Long-term outcomes of Acute Myeloid Leukemia in adults in Pakistan

Journal of the Pakistan Medical Association

Volumn 52, Issue 10, 2002, Pages 482-486

  Kakepoto, G N ^a   Burney, I A ^a   Zaki, S ^a   Adil, S N ^a   Khurshid, M ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PAKISTAN; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036823442     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sandler DP. Epidemiology of acute myelogenous leukemia. Semin. Oncol., 1987;14:359-64.
2. Gale RP, Foon, KA. Therapy for acute myelogenous leukemia. Semin. Hematol., 1987;24:40-54.
3. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation regimen with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J. Clin. Oncol., 1985;3:1583-89.
4. Rowe JM. Clinical trials in adults with acute myelogenous leukemia: The ECOG experience. In Gale, R.P. ed. Acute myelogenous leukemia: Progress and controversies. New York, Wiley-Liss, 1990, pp. 123-243.
5. Berman E, Heller G, Santorassa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 1991;77:1666-74.
6. Estey E, deLima M, Strom S, et al. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Centre. Cancer, 1997;80:2176-80.
7. Band PR, Le ND, Fang R, et al. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am. J. Epidemiol., 1996;143:137-43.
8. Bennett JM, Catovsky D, Daniel M, et al. Proposals for the classification of the acute leukemia. Br. J. Haematol., 1976;33:451-58.
9. Burney IA., Kakepoto GN, Siddiqui T, et al. All trans retinoic acid in acute promyelocytic leukaemia: case series and review of literature. J. Coll. Phycians Surgeons Pak., 1998;8:119-21.
10. Mayer RJ, Davies RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 1994;331:896-903.
11. Kaplan EL Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 1958;53:457-81.
12. Bennett JM, Begg CB. Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival. Cancer Res., 1981;41:4833-39.
13. Sultan C, Deregnaucourt J, Ko YW, et al. Distribution of 250 cases of acute myeloid leukemia (AML) according to the FAB classification and response of chemotherapy. Brit. J. Haematol., 1981;47:545-51.
14. Mertelsmann R, Thaler HT, Gee TS, et al. Morphological classification, response to therapy and survival in 263 adult patients with acute non-lymphoblastic leukemia. Blood, 1980;56:773-81.
15. Van der Reijden HJ, van Rhenen DJ, Lansdrop PM., et al. A comparison of surface marker analysis and FAB classification in acute myeloid leukemia. Blood, 1983;61:443-48.
16. Hassan K, Quresh M, Shafi S, et al. Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological features. J. Pak. Med. Assoc., 1993;43:200-3.
17. Chaudhry MT, Tayyab M, Farooqui IA. Acute Nonlymphoblastic leukemia in adults. J. Pak. Med. Assoc., 1993;43:259-61.
18. Nakase K, Bradstock K, Sartor M, et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia, 2000;14:163-68.
19. Cimino G, Rapanotti MC, Elia L, et al. ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res., 1995;55:1625-28.
20. Scheinberg SA, Maslak P, Weiss M. Acute leukaemias. In: DeVitta VT, Hellman S, Rosenberg SA. eds. Cancer: Principles and practice of oncology. 5th ed. New York, Lippincott-Raven, 1990, pp. 2293-21.
21. Mizutani S. Recent advances in the study of the Hereditary and environmental basis of childhood leukemia. Int. J. Hematol., 1998;68:131-43.
22. Kwiatkowski A. Dietary and other environmental risk factors in acute leukemias. A case control study of 119 patients. Eur. J. Cancer Prev, 1993;2:139-40.
23. Keating MJ, Smith TL, Gehan EA, et al. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer, 1982;50:457-65.
24. Bennett JM, Andersen JW, Cassileth PA. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk. Res., 1991;15:223-27.
25. Bloomfield CD, Herzig GP, Peterson BA, et al. Long-term survival of patients with acute myeloid leukemia. Updated results from two trials evaluating postinduction chemotherapy. Cancer, 1997;80:2186-90.
26. Estey E, deLima M, Strom S, et al. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D Anderson cancer centre. Cancer, 1997;80:2176-80.
27. Appelbaum FR, Kopecky KJ. Long-term survival after chemotherapy for acute myeloid leukemia. Cancer, 1997;80:2199-204.
28. Weick JK, Kopeck KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood, 1996;88:2841-51.
29. Berman E, Wiernik P, Vogler, R, et al. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer, 1997;80:2181-85.
30. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acutemyeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer, 1997;80:2205-9.